Details for New Drug Application (NDA): 210786
✉ Email this page to a colleague
The generic ingredient in NADOLOL is bendroflumethiazide; nadolol. There are four drug master file entries for this compound. Additional details are available on the bendroflumethiazide; nadolol profile page.
Summary for 210786
Tradename: | NADOLOL |
Applicant: | Novast Labs |
Ingredient: | nadolol |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 210786
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 20MG | ||||
Approval Date: | Jun 1, 2018 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 40MG | ||||
Approval Date: | Jun 1, 2018 | TE: | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 80MG | ||||
Approval Date: | Jun 1, 2018 | TE: | RLD: | No |
Complete Access Available with Subscription